1. Home
  2. RDHL vs POLA Comparison

RDHL vs POLA Comparison

Compare RDHL & POLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDHL
  • POLA
  • Stock Information
  • Founded
  • RDHL 2009
  • POLA 1979
  • Country
  • RDHL Israel
  • POLA United States
  • Employees
  • RDHL N/A
  • POLA N/A
  • Industry
  • RDHL Biotechnology: Pharmaceutical Preparations
  • POLA Industrial Machinery/Components
  • Sector
  • RDHL Health Care
  • POLA Miscellaneous
  • Exchange
  • RDHL Nasdaq
  • POLA Nasdaq
  • Market Cap
  • RDHL 3.8M
  • POLA 4.3M
  • IPO Year
  • RDHL N/A
  • POLA 2016
  • Fundamental
  • Price
  • RDHL $2.02
  • POLA $1.86
  • Analyst Decision
  • RDHL
  • POLA
  • Analyst Count
  • RDHL 0
  • POLA 0
  • Target Price
  • RDHL N/A
  • POLA N/A
  • AVG Volume (30 Days)
  • RDHL 19.3K
  • POLA 275.6K
  • Earning Date
  • RDHL 08-28-2025
  • POLA 08-13-2025
  • Dividend Yield
  • RDHL N/A
  • POLA N/A
  • EPS Growth
  • RDHL N/A
  • POLA N/A
  • EPS
  • RDHL N/A
  • POLA N/A
  • Revenue
  • RDHL $8,042,999.00
  • POLA $13,918,000.00
  • Revenue This Year
  • RDHL $381.91
  • POLA N/A
  • Revenue Next Year
  • RDHL N/A
  • POLA N/A
  • P/E Ratio
  • RDHL N/A
  • POLA N/A
  • Revenue Growth
  • RDHL 23.17
  • POLA 8.08
  • 52 Week Low
  • RDHL $1.71
  • POLA $1.53
  • 52 Week High
  • RDHL $20.28
  • POLA $4.90
  • Technical
  • Relative Strength Index (RSI)
  • RDHL 57.04
  • POLA 57.87
  • Support Level
  • RDHL $1.75
  • POLA $1.53
  • Resistance Level
  • RDHL $2.08
  • POLA $2.75
  • Average True Range (ATR)
  • RDHL 0.10
  • POLA 0.14
  • MACD
  • RDHL 0.03
  • POLA 0.03
  • Stochastic Oscillator
  • RDHL 85.16
  • POLA 27.87

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

About POLA Polar Power Inc.

Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, backup DC generators, hybrid power systems, Li-Ion battery systems, Marine DC generators, and others. The company's geographical presence is in the United States, Canada, Australia and South Pacific Islands, Asia, Europe and Middle East, United Kingdom, Other North America, South Africa, and others.

Share on Social Networks: